Elizabeth Garrett-Mayer to Biomarkers, Tumor
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Biomarkers, Tumor.
Connection Strength
0.523
-
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2012 Jan 05; 119(1):55-63.
Score: 0.290
-
Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort study. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:312-20.
Score: 0.067
-
The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol. 2008 Sep; 33(3):579-84.
Score: 0.058
-
A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 2008 Mar; 135(3):627-34.
Score: 0.056
-
Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res Treat. 2002 Dec; 76(3):255-60.
Score: 0.039
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.013